



## » APPLICATION BULLETIN

# MEVOPUR™ Special Effects Effect Colorants for Healthcare Devices and Pharmaceutical Packaging

Self-administered medication, for example via pen devices and inhalers, has been the norm for many years. However, U.S. studies indicate only 28% patient-adherence to treatment programs. Designers are looking for ways to make their devices easier to use and more attractive—special effects can help this.

When added to plastics, special effect pigments create a distinctive impression like pearlescence, sparkle or a metallic look. These have been used successfully in personal care and consumer goods to enhance the look and feel of products and increase market appeal. However, these raw materials often lack the regulatory documentation to support their use in healthcare applications.

Avient brings deep knowledge gathered from use of these pigments in a wide range of applications and combines this with the dedicated experience of the healthcare team. Ingredients used in MEVOPUR have been tested to industry standards that support applications in both medical devices and pharmaceutical packaging.\*

## KEY CHARACTERISTICS

- Manufactured at three ISO 13485 certified manufacturing sites, providing global consistency and increased security of supply
- Documented change control beyond CAS Number reducing risk of change
- Free from animal-derived substances and phthalates
- Available as pre-colored formulation or masterbatch and for use in different polymers

## REGULATORY SUPPORT

- Raw materials tested to:
  - ISO 10993-1 and USP <87> <88> biological evaluation
  - European Pharmacopeia 3.1.3/3.1.5 (polyolefin)
  - USP <661.1> (polyethylene)
  - ICH Q3D elemental impurities
- Registered Drug Master File (Type III) and/or Device Master File
- Food contact established with FDA/EU\*\*

\* Design note: Effect colors require careful consideration of part design and polymer flow paths to minimize visible flow lines. It is important to consult your Avient technical representative during initial concept design.

\*\* FDA/EU compliance information available upon request.



Healthcare use limitations apply—see below. Contact Avient for more information.

**1.844.4AVIENT**  
**www.avient.com**



Copyright © 2021, Avient Corporation. Avient makes no representations, guarantees, or warranties of any kind with respect to the information contained in this document about its accuracy, suitability for particular applications, or the results obtained or obtainable using the information. Some of the information arises from laboratory work with small-scale equipment which may not provide a reliable indication of performance or properties obtained or obtainable on larger-scale equipment. Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. Processing conditions can cause material properties to shift from the values stated in the information. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. You have the responsibility to conduct full-scale end-product performance testing to determine suitability in your application, and you assume all risk and liability arising from your use of the information and/or use or handling of any product. AVIENT MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, either with respect to the information or products reflected by the information. This literature shall NOT operate as permission, recommendation, or inducement to practice any patented invention without permission of the patent owner.

Avient products have not been designed for nor are they promoted or intended for use in:

- (a) medical devices categorized by either the United States Food and Drug Administration (FDA) or the International Standards Organization (ISO) as an “implant” device; or “Permanent” as defined under US Pharmacopoeia (USP) or ISO standards; or
- (b) active implantable medical devices as defined in EU Directive 90/385/EEC as amended; or
- (c) medical devices for “Long Term” use as defined in EU Directive 93/42/EEC as amended.

Without limiting the generality of this statement, Avient products shall not be used in any medical device application intended for:

- (1) exposure to human tissue or body fluids for 30 days or greater;
- (2) “plastic” (cosmetic or reconstructive) surgery use;
- (3) reproductive implants or any birth control device; or
- (4) any critical component in a permanently (greater than 30 days) implanted medical device that supports or sustains human life.

It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device, including the suitability of all raw materials and components used for its manufacture, and with all applicable laws and regulations.